Search

Oct 14, 2024
Lundbeck CEO Charl van Zyl describes the rationale for today's $2.6 billion acquisition of Longboard Pharma
He explains the market opportunity he sees for Bexicaserin and the data that made him comfortable to pull the trigger on the deal today...